Expert Panel Recommends New Shingles Vaccine, Shingrix, as First-Line Treatment
A new shingles vaccine that provides far more protection than its predecessor received the full blessing of a U.S. government vaccine advisory panel on Wednesday.
In a close 8-7 vote, the Advisory Committee on Immunization Practices recommended that Shingrix be chosen over Zostavax as the shingles vaccine of choice in adults aged 50 and older, the Washington Post reported.
Previously, a shingles vaccine had only been recommended for those aged 60 and older.
The panel went even further, and recommended that anyone who has been vaccinated with the Zostavax vaccine be re-vaccinated with the Shingrix vaccine -- that group numbers about 20 million people, the Post reported.
In total, more than 40 million people will be affected by the new recommendations, the newspaper said.
Shingles is an extraordinarily painful rash caused by the chickenpox virus. It tends to strike older adults.
The U.S. Food and Drug Administration had just approved Shingrix last Friday, based on a study from its maker, GlaxoSmithKline. That research found Shingrix protected about 90 percent of patients, but Zostavax only protected 50 percent of patients. Shingrix requires two shots, while Zostavax only requires one shot.
"This represents a major advance for people who want to be protected against the disease and its complications," Kathleen Dooling, a medical officer with the U.S. Centers for Disease Control and Prevention, told the Post.
The CDC, which sets immunization schedules, typically accepts the recommendations of its vaccine panel. If approved by the CDC director, the new guidelines will be published as policy early next year, the newspaper said.
Posted: October 2017
Read this next
THURSDAY, May 9, 2019 -- The virus that gave you chickenpox as a kid can rise again after decades of inactivity and inflict a painful, even blinding, eye infection in old...
WEDNESDAY, Jan. 9, 2019 -- Newly diagnosed cancer patients may be at increased risk for the painful skin condition shingles, a new study finds. Experts say development of new...
THURSDAY, Oct. 26, 2017 -- On the heels of approval of a better vaccine for the painful condition shingles, adults over 50 should plan to roll up their sleeves -- again. The new...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.